The prognostic value of breast cancer resistance protein (BCRB/ABCG2) expression in breast carcinomas

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 31, Issue 4, 2012, Pages 367-376

  Omran, Ola M ^a,b  

^a QASSIM UNIVERSITY   (Saudi Arabia)

^b ASSIUT UNIVERSITY   (Egypt)

Author keywords

ABCG2; Breast carcinoma; HER2; Immunohistochemistry

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN;

EID: 84873312506     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvironPatholToxicolOncol.2013006767     Document Type: Article

References (49)

1. Bombonati A, Sgroi DC. The molecular pathology of breast cancer progression. J Pathol. 2011;223:307-317.
2. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBO-CAN 2000: cancer incidence, mortality and prevalence worldwide version 1.0. IARC Cancer Base No. 5. Lyon: IARC Press; 2001.
3. Barrett SV. Breast cancer. J R Coll Physicians Edinb. 2010;40:335-338.
4. Mo W, Zhang JT. Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol. 2012; 3:1-27.
5. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ and Schellens JH. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001;61:3458-3464.
6. Jonker JW, Merino G, Musters S, van Herwaarden AE, Bolscher E, Wagenaar E, Mesman E, Dale TC, Schinkel AH. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med. 2005;11:127-129.
7. Zhang JT. Use of arrays to investigate the contribution of ATP-binding cassette transporters to drug resistance in cancer chemotherapy and prediction of chemosensitivity. Cell Res. 2007;17:311-323.
8. Moulder S. Intrinsic resistance to chemotherapy in breast cancer. Womens Health (Lond Engl). 2010; 821-30.
9. Robey RW, To KK, Polgar O, Dohse M, Fetsch P, Dean M, Bates SE. ABCG2: A perspective. Adv Drug Deliv Rev. 2009;61:3-13.
10. Kanzaki A, Toi M, Nakayama K, Bando H, Mutoh M, Uchida T, Fukumoto M, Takebayashi Y. Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn J Cancer Res. 2001;92:452-458.
11. Faneyte IF, Kristel PM, Maliepaard M, Scheffer GL, Scheper RJ, Schellens JH, van De Vijver MJ. Expression of the breast cancer resistance protein in breast cancer. Clin Cancer Res. 2002;8:1068-1074.
12. Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JG, Wiemer EA, Stoter G, Nooter K. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: Correlation with chemotherapeutic response. Clin Cancer Res. 2003;9:827-836.
13. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science. 1985;229:974-976.
14. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
15. Xiang L, Su P, Xia S, Liu Z, Wang Y, Gao P, Zhou G. ABCG2 is associated with HER-2 expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma. Diagn Pathol. 2011;6:90.
16. Tavassoli FA, Devilee P. Intraductal proliferative lesions. Pathology and genetics of tumors of the breast and female genetic organs. Lyon: International Agency for Research on Cancer (IARC) Press; 2003.
17. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF; American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.
18. Stein U, Lage H, Jordan A, Walther W, Bates SE, Litman T, Hohenberger P, Dietel M. Impact of BCRP/MXR, MRP1 and MDR1/PGlycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells. Int J Cancer. 2002;97:751-760.
19. Robey RW, Polgar O, Deeken J, To KW, Bates SE. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev. 2007;26:39-57.
20. Benderra Z, Faussat AM, Sayada L, Perrot JY, Chaoui D, Marie JP, Legrand O. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res. 2004;10:7896-7902.
21. Benderra Z, Faussat AM, Sayada L, Perrot JY, Tang R, Chaoui D, Morjani H, Marzac C, Marie JP, Le-grand O. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res. 2005;11:7764-7772.
22. Uggla B, Stahl E, Wagsater D, Paul C, Karlsson MG, Sirsjo A, Tidefelt U. BCRP mRNA expression v. clinical outcome in 40 adult AML patients. Leuk Res. 2005;29:141-146.
23. Suvannasankha A, Minderman H, O'Loughlin KL, Nakanishi T, Greco WR, Ross DD, Baer MR. Breast cancer resistance protein (BCRP/MXR/ ABCG2) in acute myeloid leukemia: discordance between expression and function. Leukemia. 2004;18:1252-1257.
24. Tsunoda S, Okumura T, Ito T, Kondo K, Ortiz C, Tanaka E, Watanabe G, Itami A, Sakai Y, Shimada Y. ABCG2 expression is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma. Oncology. 2007;71:251-258.
25. Yoh K, Ishii G, Yokose T, Minegishi Y, Tsuta K, Goto K, Nishiwaki Y, Kodama T, Suga M, Ochiai A. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res. 2004;10:1691-1697.
26. Shen B, Dong P, Li D, Gao S. Expression and function of ABCG2 in head and neck squamous cell carcinoma and cell lines. Exp Ther Med. 2011;2:1151-1157.
27. Shukla S, Zaher H, Hartz A, Bauer B, Ware JA, Ambudkar SV. Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009;26:480-487.
28. Zhang S, Yang X, Morris ME. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol. 2004;65:1208-1216.
29. Vore M, Leggas M. Progesterone acts via progesterone receptors A and B to regulate breast cancer resistance protein expression. Mol Pharmacol. 2008;73:613-615.
30. Ee PL, He X, Ross DD and Beck WT. Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference. Mol Cancer Ther. 2004;3:1577-1583.
31. Li WT, Zhou GY, Song XR, Chi WL, Ren RM, Wang XW. Modulation of BCRP mediated atypical multidrug resistance phenotype by RNA interference. Neoplasma. 2005;52:219-224.
32. Priebsch A, Rompe F, Tonnies H, Kowalski P, Surowiak P, Stege A, Materna V, Lage H. Complete reversal of ABCG2-depending atypical multidrug resistance by RNA interference in human carcinoma cells. Oligonucleotides. 2006;16:263-274.
33. Gong C, Yao H, Liu Q, Chen J, Shi J, Su F, Song E. Markers of tumor-initiating cells predict chemoresistance in breast cancer. PLoS One. 2010;5:e15630.
34. Liu AN, Sun P, Liu JN, Ma JB, Qu HJ, Zhu H, Yu CY, Zhang LM. Clinicopathologic characteristics and prognostic factors in patients with operable HER-2 overexpressing breast cancer. Asian Pac J Cancer Prev. 2012;13:1197-1201.
35. Park K, Kim J, Lim S, Han S, Lee JY. Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray. Mod Pathol. 2003;16:937-943.
36. Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utrainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol. 2009;27:5685-5692.
37. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jachisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD, Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672.
38. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrehbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684.
39. Schimmelpenning H, Eriksson ET, Falkmer UG, Azavedo E, Svane G, Aur GU. Expression of the c-erbB-2 proto-oncogene product and nuclear DNA content in benign and malignant human breast parenchyma. Virchows Arch A Pathol Anat Histopathol. 1992;420:433-440.
40. Pavelic ZP, Pavelic L, Lower EE, Gapany M, Gapany S, Banker EA. C-myc, c-erbB-2, and Ki67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. Cancer Res. 1992;52:2597-2602.
41. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL. Overexpression of HER2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992;23:974-979.
42. Liu E, Thor A, He M, Barcos M, Ljung BM, Benz C. The HER2 (c-erbB-2) oncogene is frequently amplified in situ carcinomas of the breast. Oncogene. 1992;7:1027-1032.
43. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Söderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R, et al. Prognostic importance of c-erbB-2 expression in Breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992;10:1049-1056.
44. Iglehart JD, Kerns B-J, Huper G, Marks JR. Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer. Breast Cancer Res Treat. 1995;34:253-263.
45. Somerville JE, Clarke LA, Biggart JD. c-erbB-2 over expression and histological type of in situ and invasive breast cancer. J Clin Pathol. 1992;45:16-20.
46. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008;21:8-15.
47. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, Holland EC. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell. 2009;4:226-235.
48. Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE, Sarkadi B, Sorrentino BP, Schuetz JD. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem. 2004;279:24218-24225.
49. Goler-Baron V, Sladkevich I, Assaraf YG. Inhibition of the PI3K-Akt signaling pathway disrupts ABCG2-rich extracellular vesicles and overcomes multidrug resistance in breast cancer cells. Biochem Pharmacol. 2012;83:1340-1348.